Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:BCT CVE:HEM CVE:LTY CVE:RVV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTBriaCell TherapeuticsC$10.60-3.8%C$10.60C$3.50▼C$15.75C$168.68MN/A12,671 shs3,402 shsHEMHemostemixC$0.13+8.7%C$0.11C$0.06▼C$0.43C$22.25M1.193301376,001 shs54,677 shsLTYLiberty BiopharmaC$2.00+∞C$2.00C$0.06▼C$2.74C$21.54MN/A23,286 shs700 shsRVVRevive TherapeuticsC$0.08+14.3%C$0.08C$0.07▼C$0.25C$5.79MN/A93,085 shs212,852 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTBriaCell Therapeutics0.00%0.00%0.00%0.00%0.00%HEMHemostemix-8.00%+9.52%+43.75%-23.33%+64.29%LTYLiberty Biopharma0.00%0.00%0.00%0.00%0.00%RVVRevive Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTBriaCell TherapeuticsC$10.60-3.8%C$10.60C$3.50▼C$15.75C$168.68MN/A12,671 shs3,402 shsHEMHemostemixC$0.13+8.7%C$0.11C$0.06▼C$0.43C$22.25M1.193301376,001 shs54,677 shsLTYLiberty BiopharmaC$2.00+∞C$2.00C$0.06▼C$2.74C$21.54MN/A23,286 shs700 shsRVVRevive TherapeuticsC$0.08+14.3%C$0.08C$0.07▼C$0.25C$5.79MN/A93,085 shs212,852 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTBriaCell Therapeutics0.00%0.00%0.00%0.00%0.00%HEMHemostemix-8.00%+9.52%+43.75%-23.33%+64.29%LTYLiberty Biopharma0.00%0.00%0.00%0.00%0.00%RVVRevive Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTBriaCell Therapeutics 0.00N/AC$15.0041.51% UpsideHEMHemostemix 0.00N/AN/AN/ALTYLiberty Biopharma 0.00N/AN/AN/ARVVRevive Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTBriaCell TherapeuticsN/AN/AC$3.34 per share3.17C$3.60 per shareN/AHEMHemostemixN/AN/AC$0.01 per share10.77C($0.10) per shareN/ALTYLiberty BiopharmaN/AN/AC$0.00 per share2,000.00C$0.79 per shareN/ARVVRevive TherapeuticsN/AN/AC$0.03 per share3.18C$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTBriaCell TherapeuticsN/A-C$0.38N/A∞N/AN/AN/AN/AN/AHEMHemostemix-C$5.00M-C$0.03N/A∞N/AN/A37.07%-349.24%N/ALTYLiberty BiopharmaN/A-C$0.16N/A∞N/AN/AN/AN/AN/ARVVRevive TherapeuticsN/A-C$0.02N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTBriaCell TherapeuticsN/AN/AN/AN/AN/AHEMHemostemixN/AN/AN/AN/AN/ALTYLiberty BiopharmaN/AN/AN/AN/AN/ARVVRevive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTBriaCell Therapeutics0.05129.63128.68HEMHemostemix-55.070.040.48LTYLiberty Biopharma8.190.120.12RVVRevive TherapeuticsN/A6.146.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTBriaCell TherapeuticsN/AHEMHemostemixN/ALTYLiberty BiopharmaN/ARVVRevive TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipBCTBriaCell TherapeuticsN/AHEMHemostemix10.43%LTYLiberty BiopharmaN/ARVVRevive TherapeuticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTBriaCell Therapeutics515.91 millionN/ANot OptionableHEMHemostemixN/A178.01 millionN/ANot OptionableLTYLiberty BiopharmaN/A10.77 millionN/ANot OptionableRVVRevive TherapeuticsN/A72.41 millionN/ANot OptionableRVV, LTY, BCT, and HEM HeadlinesRecent News About These CompaniesRevive Therapeutics Updates on Nerve Agent Countermeasure StudyAugust 19, 2025 | theglobeandmail.comRevive Therapeutics Ltd.: Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt SettlementAugust 12, 2025 | finanznachrichten.deRevive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study - MorningstarJuly 10, 2025 | morningstar.comM2025-07-08 | Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study | CSE:RVV | Press Release - StockhouseJuly 10, 2025 | stockhouse.comRevive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure StudyJuly 8, 2025 | financialpost.comF2025-06-26 | Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant ... - StockhouseJune 28, 2025 | stockhouse.comRevive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling OpportunityJune 26, 2025 | financialpost.comFRevive Therapeutics Ltd.June 4, 2025 | barrons.comRevive Therapeutics Advances Next-Gen Bucillamine for Critical Medical NeedsJune 4, 2025 | tipranks.comRevive Therapeutics Advances with Next-Generation Bucillamine DevelopmentJune 4, 2025 | financialpost.comFRevive Therapeutics Ltd.: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureMay 13, 2025 | finanznachrichten.deRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureMay 12, 2025 | financialpost.comFRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureMay 12, 2025 | financialpost.comFRevive Therapeutics Ltd. (RVV.NE)April 18, 2025 | ca.finance.yahoo.comRevive Therapeutics Ltd.: Revive Therapeutics to Investigate Bucillamine's Potential in Cancer TreatmentApril 10, 2025 | finanznachrichten.deRevive Therapeutics to Investigate Bucillamine’s Potential in Cancer TreatmentApril 10, 2025 | financialpost.comFRevive Therapeutics Announces Acquisition of Molecular Hydrogen ProgramApril 1, 2025 | markets.businessinsider.comDiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral SclerosisMarch 3, 2025 | markets.businessinsider.comRevive Therapeutics buys DiagnaMed’s molecular hydrogen intellectual propertyMarch 3, 2025 | greenmarketreport.comGRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureJanuary 8, 2025 | financialpost.comFNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Brinker Serves Up Earnings Beat, Sidesteps Cost PressuresBy Chris Markoch | August 14, 20253 Stocks Poised to Gain from a September Rate CutBy Chris Markoch | September 4, 2025RVV, LTY, BCT, and HEM Company DescriptionsBriaCell Therapeutics CVE:BCTC$10.60 -0.42 (-3.81%) As of 12/30/2021BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.Hemostemix CVE:HEMC$0.12 +0.01 (+8.70%) As of 03:45 PM EasternHemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.Liberty Biopharma CVE:LTYC$2.00 +2.00 (+∞) As of 10/10/2018Liberty Biopharma Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of an automated bioprocessing and cell isolation technology. Its technology is used in the isolation of regenerative cells from human adipose tissues for use in research, cosmetic and aesthetic medicine, burn management, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, and hepatic disease and kidney disease. The company was formerly known as Avagenesis Corp. and changed its name to Liberty Biopharma Inc. in January 2017. Liberty Biopharma Inc. is based in Richmond, Canada.Revive Therapeutics CVE:RVVC$0.08 +0.01 (+14.29%) As of 07/22/2019Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
